NASDAQ:TENX Tenax Therapeutics Q2 2026 Earnings Report $13.46 -0.87 (-6.06%) As of 11:18 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Tenax Therapeutics EPS ResultsActual EPS-$0.35Consensus EPS -$0.38Beat/MissBeat by +$0.03One Year Ago EPSN/ATenax Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATenax Therapeutics Announcement DetailsQuarterQ2 2026Date7/31/2026TimeBefore Market OpensConference Call DateFriday, July 31, 2026Conference Call Time7:30AM ETUpcoming EarningsTenax Therapeutics' Q3 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Tenax Therapeutics Earnings HeadlinesTenax Therapeutics' (TENX) "Buy" Rating Reiterated at Chardan CapitalAugust 3 at 1:36 AM | americanbankingnews.comChardan Capital Initiates a Buy Rating on Tenax Therapeutics (TENX)August 2 at 7:12 AM | theglobeandmail.com"Second Wave” Hitting Iran Soon? Wall Street Issues WarningAnalysts at Goldman Sachs and Morgan Stanley are warning that a quiet domestic threat - unrelated to overseas conflict - could be the worst thing to hit American investors in 50 years, potentially keeping portfolios in the red for a decade or more. TradeSmith CEO Keith Kaplan is responding with an AI-driven trading tool built by a former U.S. Air Force nuclear missile coder, designed to sidestep sudden market crashes while still growing your money - regardless of whether markets rise, fall, or stay flat. No options, gold, crypto, or penny stocks involved.August 4 at 1:00 AM | TradeSmith (Ad)Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateJuly 31, 2026 | globenewswire.comCantor Fitzgerald Reaffirms Overweight Rating for Tenax Therapeutics (NASDAQ:TENX)July 31, 2026 | americanbankingnews.comCanaccord Genuity Group Initiates Coverage on Tenax Therapeutics (NASDAQ:TENX)July 30, 2026 | americanbankingnews.comSee More Tenax Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tenax Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenax Therapeutics and other key companies, straight to your email. Email Address About Tenax TherapeuticsTenax Therapeutics (NASDAQ:TENX) is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications. Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions. The company conducts preclinical and clinical studies under the guidance of U.S. Food and Drug Administration regulations and is advancing its most advanced candidates toward pivotal trials. Headquartered in Exton, Pennsylvania, Tenax Therapeutics serves hospitals, surgery centers and other healthcare facilities primarily in North America. The company collaborates with academic institutions and strategic partners to advance its pipeline. Tenax is managed by a team of executives with backgrounds in pharmaceutical development and commercialization, and it is publicly traded on the NASDAQ under the ticker symbol TENX.View Tenax Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Dodging Deutsche Telekom: T-Mobile's Strategic WinSpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have ControlTyson Foods Offers a Meaty Opportunity for Income InvestorsStrategy's Structural Strength: Hidden in a $8 Billion IllusionMarketBeat Week in Review – 07/27- 07/31A Sweet Beat and a Wearables Rally Came With Reasons to PauseChevron’s Strong Quarter Shows Why It Still Leads the Energy Sector Upcoming Earnings DoorDash (8/5/2026)Walt Disney (8/5/2026)MercadoLibre (8/5/2026)Occidental Petroleum (8/5/2026)Phillips 66 (8/5/2026)Allstate (8/5/2026)Brookfield Asset Management (8/5/2026)MetLife (8/5/2026)Manulife Financial (8/5/2026)Block (8/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
